Sedia™ BED HIV-1 Incidence EIA

CDC Approved Sedia™ BED HIV-1 Incidence EIA to Determine Recency of Infection and Estimate HIV-1 Incidence.

The Sedia™ BED HIV-1 Incidence EIA is an in vitro quantitative enzyme immunoassay for distinguishing recent from longer-term HIV-1 infections. The test accomplishes this by measuring the proportion of HIV-1 specific IgG to total IgG in liquid plasma and serum and, when supplemented with the Sedia™ BED HIV-1 Incidence EIA Dried Blood Spot Controls Pack, dried blood, serum or plasma spots. The assay was developed as an epidemiological tool for intervention programs, resource management, and detailed population surveillance.

Using technology originally developed by the U.S. Centers for Disease Control and Prevention (CDC) and first commercialized by Sedia scientists in 2004, the Sedia™ BED HIV-1 Incidence EIA is an important epidemiological tool for fighting the HIV epidemic. The test has been adopted in many countries around the world, including in the U.S. National HIV Surveillance program.

Customers who wish to test dried blood, serum or plasma specimens instead of liquid serum or plasma specimens should also order the supplemental Cat. No. 1001 Sedia™ BED HIV-1 Incidence EIA Dried Blood Spot Controls Pack.

For Research Use Only. Not for Use in Diagnostic Procedures.

Ordering Information

Cat. No. 1000	Sedia™ BED HIV-1 Incidence EIA, 192 Tests
Cat. No. 1001	Sedia™ BED HIV-1 Incidence EIA Dried Blood Spot Controls Pack, 20 Cards (click here for more information)

Recent Improvements

More 10X Washer Buffer Concentrate is provided (200 mL)
10X Wash Buffer Concentrate is now interchangeable and compatible with 10X Wash Buffer Concentrate of Sedia™ HIV-1 LAg-Avidity EIA for our customers who wish to use both assays in their plate washer equipment.
Improved stability of diluted (1X) Wash Buffer (stable at 2-30ºC for up to 1 month).
More versatile EIA Assay Plate Design (no longer limited to 8-well strips, user can run any multiple of single wells).

U.S. CDC Approved

Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.

Use of the Sedia™ BED HIV-1 Incidence EIA in the U.S.

The SEDIA™ BED HIV-1 Incidence EIA is for Research Use Only and Not for Use in Diagnostic Procedures. Users of the Sedia™ BED HIV-1 Incidence EIA based in the U.S. are required to complete and submit a Certification Regarding Research Use (download here) prior to shipment of the product certifying that use of the product will be used for research use only in compliance with FDA regulations.

Top

Sedia™ BED HIV-1 Incidence EIA

CDC Approved Sedia™ BED HIV-1 Incidence EIA to Determine Recency of Infection and Estimate HIV-1 Incidence.

U.S. CDC Approved

Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.

Use of the Sedia™ BED HIV-1 Incidence EIA in the U.S.

Product Downloads

Other Resources

Latest Sedia Bio News

Sedia™ BED HIV-1 Incidence EIA

CDC Approved Sedia™ BED HIV-1 Incidence EIA to Determine Recency of Infection and Estimate HIV-1 Incidence.

U.S. CDC Approved Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release. Certification of U.S. CDC testing and approval is provided with each assay kit.

Use of the Sedia™ BED HIV-1 Incidence EIA in the U.S.

Product Downloads

Other Resources

Latest Sedia Bio News

U.S. CDC Approved

Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.